Valneva's Lyme disease vaccine candidate - VLA15
Lyme disease is the most common vector-borne illness in the Northern Hemisphere. Valneva's candidate is the only vaccine in clinical development worldwide.
Valneva reported positive Phase 1 interim data for its Lyme disease vaccine candidate VLA15 (Press release
). The Company has successfully concluded the end of Phase 1 process for this candidate with the Food and Drug Administration (FDA) and has obtained alignment with regard to its Phase 2 strategy (Press release
Valneva is now finalizing details for Phase 2 and, subject to regulatory clearances, will enter Phase 2 clinical development at the end of 2018.
Valneva´s vaccine candidate VLA15, under Fast Track Designation by the FDA, is a multivalent vaccine that targets the outer surface protein A (OspA) of Borrelia. Pre-clinical data showed that VLA15 has the potential for protection against the majority of Borrelia species pathogenic for humans (Source).
The global market for a vaccine against Lyme disease is currently estimated at approximately €700 - €800 million annually1.
About Lyme disease
This program is supported by the Vienna Business Agency.1 Company estimate supported by independen market studies